Clinical Trial Update: Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Ianalumab (VAY736) in active Sjögren's syndrome is ongoing but not currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sjögren Syndrome

Drugs mentioned

• Ianalumab (ianalumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Sjogren Syndrome | Phase 3 | Status: ACTIVE_NOT_RECRUITING